128 results on '"Azodi, M"'
Search Results
2. Patient experience with medical marijuana in women with gynecologic malignancies: A single-institution survey-based study
3. The PARP inhibitor niraparib demonstrates preclinical activity against HRD-deficient carcinosarcomas
4. Chemotherapy choice and impact on survival of patients with carcinosarcoma of the ovary: A retrospective review
5. Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress HER2/Neu (NCT01367002): Updated survival analysis
6. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab-govitecan
7. Safety and Efficacy Results of Retreatment With a PARP Inhibitor Monotherapy in Late-Line Recurrent Ovarian Cancer: Results From a Subset of the QUADRA Trial
8. Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation
9. Sacituzumab govitecan (IMMU-132) in uterine serous carcinoma
10. Primary cytoreductive surgery versus neoadjuvant chemotherapy for advanced-stage uterine malignancies
11. The combination of olaparib (Poly ADP-ribose polymerase inhibitor) with neratinib (pan-HER inhibitor) is synergistic in epithelial ovarian carcinoma overexpressing HER2.
12. Surgical approach for interval debulking after neoadjuvant chemotherapy for treatment of advanced-stage ovarian cancer
13. Impact of carboplatin hypersensitivity and desensitization on overall survival in patients with recurrent ovarian cancer
14. Remarkable in vitro and in vivo activity of IMGN853, an antibody-drug conjugate targeting folate receptor alpha linked to the tubulin-disrupting maytansinoid DM4, in biologically aggressive (type II) endometrial cancers
15. Does the use of manipulator for endometrial cancer surgery lead to increased use of adjuvant therapy?
16. Neratinib shows efficacy in the treatment of HER2/neu amplified epithelial ovarian carcinoma in vitro and in vivo
17. Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer
18. Endometrial carcinoma as the presenting malignancy in an 18-year-old patient with Li-Fraumeni syndrome
19. PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
20. Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo
21. Mutations in the PIK3 pathway as a major determinant of trastuzumab resistance in uterine serous carcinoma
22. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo
23. Choice of adjuvant chemotherapy following neoadjuvant carboplatin/paclitaxel and interval debulking
24. Cervical adenocarcinoma in situ: An institutional retrospective review of surgical management and outcome
25. Abstract number 8: Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study
26. Solitomab, an EpCAM/CD3 bispecific antibody (BiTE®), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo
27. Weekly ixabepilone with or without concurrent bevacizumab in the treatment of platinum/taxane-resistant endometrial and ovarian cancers: An institutional experience
28. Risk factors for omental metastasis in clinical stage I endometrial cancer: A meta-analysis
29. Class III beta-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel
30. Presentation and management of borderline ovarian tumors: Should mucinous tumors be managed differently?
31. Ovarian versus uterine serous carcinomas: Clinicopathologic and miRNA analysis
32. Institutional review of primary lymphoma of the female genital tract: A 32-year experience
33. Mammaglobin B (SCGB2A1)-specific CD8+ cytotoxic T lymphocytes (CTL) are highly effective in killing autologous chemotherapy resistant ovarian cancer cells: Implications for SCGB2A1 dendritic cell-based therapeutic vaccines
34. A phase I clinical trial of the mTOR inhibitor everolimus in combination with oral topotecan for patients with recurrent and advanced endometrial cancer
35. Uterine serous papillary carcinomas overexpress human trophoblast cell surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody
36. Cervical adenocarcinoma in situ: An institutional retrospective review of surgical management and outcome
37. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo
38. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease☆
39. Extrarenal Wilms' tumor of the uterine corpus
40. Abstract number 8: Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study
41. Solitomab, an EpCAM/CD3 bispecific antibody (BiTE®), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo
42. Weekly ixabepilone with or without concurrent bevacizumab in the treatment of platinum/taxane-resistant endometrial and ovarian cancers: An institutional experience
43. Institutional review of primary lymphoma of the female genital tract: A 32-year experience
44. Presentation and management of borderline ovarian tumors: Should mucinous tumors be managed differently?
45. Class III beta-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel
46. Risk factors for omental metastasis in clinical stage I endometrial cancer: A meta-analysis
47. Mammaglobin B (SCGB2A1)-specific CD8 + cytotoxic T lymphocytes (CTL) are highly effective in killing autologous chemotherapy resistant ovarian cancer cells: Implications for SCGB2A1 dendritic cell-based therapeutic vaccines
48. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.
49. Corrigendum to "Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma".
50. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.